TYME

Anebulo Pharmaceuticals Announces New CEO

Retrieved on: 
Friday, October 6, 2023
Cannabis, Mental Health, Health, Natural Resources, Clinical Trials, Pharmaceutical, Biotechnology, Patent, Multimedia, Cystic Fibrosis Foundation, Retirement, AFL, Plasma, Dallas Cowboys, NFL, Dallas, Observational study, Safety, Drug Quality and Security Act, Patient, Cystic fibrosis, CB1, Factitious disorder, Annual report, National Football League, Medication, Drug discovery, Sanofi, Risk, Roche, Cannabinoid, Boehringer Ingelheim, ACI, Pharmaceutical industry, Fine chemical, TYME

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) ("Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI"), today announced that Richie Cunningham has been appointed as Anebulo’s Chief Executive Officer, replacing Simon Allen.

Key Points: 
  • Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) ("Anebulo"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication ("ACI"), today announced that Richie Cunningham has been appointed as Anebulo’s Chief Executive Officer, replacing Simon Allen.
  • His leadership and expertise in the biopharmaceutical industry will be valuable as Anebulo prepares for phase 3 development of ANEB-001," said Joseph F. Lawler, Founder and Chairman.
  • Most recently, Mr. Cunningham served as CEO at Tyme where he led the company through a merger with Syros Pharmaceuticals.
  • Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder.

NICE Actimize Powers Innovation for GoTyme Bank with its Cloud Financial Crime Digital Banking Platform

Retrieved on: 
Thursday, September 21, 2023
Banking, Fintech, Professional Services, Finance, Partnership, TYME, NICE Ltd., Trust, AI, NICE, Cryptocurrency

NICE Actimize, a NICE (Nasdaq: NICE) business, announced that it has finalized the implementation of its financial crime solutions with GoTyme Bank, a partnership between the Gokongwei Group and Singapore-based digital banking group Tyme.

Key Points: 
  • NICE Actimize, a NICE (Nasdaq: NICE) business, announced that it has finalized the implementation of its financial crime solutions with GoTyme Bank, a partnership between the Gokongwei Group and Singapore-based digital banking group Tyme.
  • NICE Actimize’s advanced AI and analytics solutions will provide support in financial crime fraud prevention, which aligns with the bank’s customer service and growth strategy.
  • “When we selected NICE Actimize to support our launch, we sought a provider that could offer rapid deployment and an innovative approach to digital financial crime management.
  • We are pleased to build a relationship with industry leader NICE Actimize, the gold standard of trust, reliability, and compliance that we offer our customers.”
    “As innovators in collective intelligence and real-time analytics, NICE Actimize looks forward to supporting GoTyme’s new digital banking platform,” said Craig Costigan, CEO, NICE Actimize.

Veritas Farms Acquires ASYSTEM and ASYSTEM Labs as Part of Growth Strategy to Build the Next Generation of Innovative Wellness Brands

Retrieved on: 
Monday, August 28, 2023
Saks, University of Nottingham, Marketing, Oli, JetBlue, Omnicom Group, Economics, Estée Lauder, Vitamin, Acquisition, TYME, H&M, Saatchi, WeWork, OTCQB, Veritas, Prologis, Organization, TSX, Growth, Warner Bros., BBDO, CMO, Beauty, Sustainability, Walmart, Chanel, SoulCycle, DC Comics, CBD, Link, BA, Partnership, Saks Fifth Avenue, Saatchi & Saatchi, Erewhon, P&G, Health, Retail, Sales, Amusement park, Management, Fashion design, Aritzia, Unilever, Nordstrom

The goal of this strategy is to better position Veritas Farms on a path to profitability and increased cash flow.

Key Points: 
  • The goal of this strategy is to better position Veritas Farms on a path to profitability and increased cash flow.
  • The acquisition will complement Veritas’ focus of helping people unlock their potential through the use of supplements and leverage Veritas' infrastructure to accelerate the growth of ASYSTEM and build the next generation of innovative wellness brands.
  • ASYSTEM Labs offers brand and product development services to consumer brands, celebrities and creators seeking to unlock the huge potential of the supplements, vitamins, and nutritional products category.
  • ASYSTEM and ASYSTEM Labs are incredible brands and a quintessential emblem of best-in-class, science-forward supplements.

Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 2, 2023
Oncology, Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, CR, Safety, Azacitidine, FDA, AML, Bone marrow, Toxicity, ASH, Society, GBT, Patient, Venetoclax, PIPE, ID, APL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CCR, Webcast, G&A, MDS, RARA, Food, Acquisition, Completeness, Physician, Pharmaceutical industry, Medical imaging, Cryptocurrency, Pfizer, TYME, Syros

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.
  • Report pivotal complete response (CR) data from the SELECT-MDS-1 Phase 3 trial in the third quarter of 2024.
  • Revenues were negative $0.8 million for the fourth quarter of 2022, as compared to $7.8 million in the fourth quarter in 2021.
  • ET to discuss these fourth quarter and full year 2022 financial results and provide a corporate update.

Syros and Tyme Technologies Announce Stockholder Approval of Merger

Retrieved on: 
Thursday, September 15, 2022
Securities Exchange Act of 1934, CDK7, Safety, Breast, COVID-19, PIPE, Mergers and acquisitions, Twitter, Risk, Sale, Acute promyelocytic leukemia, Securities Act of 1933, Sarcoma, Computershare, Nature, LinkedIn, Gene, Prostate, Intellectual property, Review, Forward-looking statement, Bangladesh Securities and Exchange Commission, Government, Patient, CUSIP, Book, Cancer, Exercise, Goal, Acute myeloid leukemia, Annual report, RARA, NASDAQ, Form, Security (finance), Prospectus, SEC, Proxy, GLOBE, Genome, Hematological Cancer Research Investment and Education Act, Failure, Freedom, Register, Arsenic trioxide, Lumber, TYME, Nasdaq, Syros

CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME’s special meeting, TYME’s stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the “Merger Agreement”), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the “Merger”). At Syros’ special meeting, Syros’ stockholders also voted in favor of all proposals, including the proposal to approve the issuance of shares of Syros’ common stock to holders of TYME’s common stock in connection with the Merger and to certain of Syros’ investors in connection with a concurrent private investment in public equity (“PIPE”) financing.

Key Points: 
  • At TYMEs special meeting, TYMEs stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the Merger Agreement), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the Merger).
  • The closings of the Merger and the PIPE financing are anticipated to take place on or around Friday, September 16, 2022.
  • Syros common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on Monday, September 19, 2022.
  • The new CUSIP number for Syros common stock following the reverse stock split is 87184Q206.

Syros and Tyme Technologies Announce Stockholder Approval of Merger

Retrieved on: 
Thursday, September 15, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Securities Exchange Act of 1934, CDK7, Safety, Breast, COVID-19, PIPE, Mergers and acquisitions, Twitter, Risk, Sale, Acute promyelocytic leukemia, Securities Act of 1933, Sarcoma, Computershare, Nature, LinkedIn, Gene, Prostate, Intellectual property, Review, Forward-looking statement, Bangladesh Securities and Exchange Commission, Government, Patient, CUSIP, Book, Cancer, Exercise, Goal, Acute myeloid leukemia, Annual report, RARA, Medication, NASDAQ, Form, Security (finance), Prospectus, SEC, Proxy, Genome, Hematological Cancer Research Investment and Education Act, Failure, Freedom, Register, Arsenic trioxide, Lumber, TYME, Nasdaq, Syros

At TYMEs special meeting, TYMEs stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the Merger Agreement), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the Merger).

Key Points: 
  • At TYMEs special meeting, TYMEs stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the Merger Agreement), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the Merger).
  • Syros common stock will begin trading on Nasdaq on a split-adjusted basis when the market opens on Monday, September 19, 2022.
  • The new CUSIP number for Syros common stock following the reverse stock split is 87184Q206.
  • Syros board of directors approved the reverse stock split at a ratio of 1-for-10 on September 15, 2022.

TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme

Retrieved on: 
Wednesday, September 7, 2022
Breast, Prospectus, Securities Act of 1933, Proxy, Glass Lewis, Forward-looking statement, U.S. Securities and Exchange Commission, GLOBE, Flagship Pioneering, Nasdaq, Company, Risk, Cancer, Sarcoma, Government, Sale, SEC, Communication, Eastern Time Zone, Intellectual property, Registration statement, Security (finance), Hematological Cancer Research Investment and Education Act, Securities Exchange Act of 1934, NASDAQ, Glass, PIPE, Special, Prostate, Review, Nature, Register, Person, Goal, Biotechnology, ISS, Failure, Form, Annual report, Compte rendu, Plan, Holding company, Bank, Director, Syros, Shareholder, TYME

ISS and Glass Lewis are leading independent, third-party proxy advisory firms who, among other services, provide proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.

Key Points: 
  • ISS and Glass Lewis are leading independent, third-party proxy advisory firms who, among other services, provide proxy voting recommendations to pension funds, investment managers, mutual funds and other institutional shareholders.
  • Upon closing of the merger, Tyme will become a wholly owned subsidiary of Syros.
  • Concurrent with the merger, Syros announced a $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94.
  • The Registration Statement and the Proxy Statement/Prospectus contain important information about Syros, Tyme, the merger and related matters.

TYME TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME

Retrieved on: 
Wednesday, August 10, 2022
Class Action Lawsuit, Professional Services, Legal, Company, Nasdaq, Sale, LLC, KSF, TYME, Syros

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of TYME Technologies, Inc. (NasdaqCM: TYME) to Syros Pharmaceuticals, Inc. (NasdaqGS: SYRS).
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Women's World Banking Announces 2023 Fintech Innovation Challenge to Elevate Fintechs with New Solutions to Close the Gender Gap in Financial Services

Retrieved on: 
Wednesday, August 3, 2022
Zero, Department of Foreign Affairs and Trade, Digital, Department, Marketing, Ernst & Young, Singapore FinTech Festival, DFAT, Swedish International Development Cooperation Agency, Female, Global Network for Rights and Development, Competition, Multimedia, Santa Clara University, Seumas McNally Grand Prize, Man, Women's World Banking, Policy, Economy, Foreign Affairs, Technology, SIDA, NEW, CEO, Challenge, Leadership, Prize, Global Television Network, Social entrepreneurship, UX, Empowerment, Bill, Growth, Birth control, Bank, TYME, Woman

NEW YORK, Aug. 3, 2022 /PRNewswire/ -- Women's World Banking announced today the 2023 Fintech Innovation Challenge, a global competition to highlight and advance solutions to close the gender gap through digital financial services. Now in its fourth year and the only women-centered fintechs competition, the Challenge will provide a platform for later stage fintechs working to address the persistent challenges in serving the low-income women's market.

Key Points: 
  • Digital financial services can serve as an on-ramp for low-income women to adopt and use a large suite of formal financial products and services, expanding women's choices and their financial and economic resilience and empowerment.
  • Low-income women represent a large, untapped market opportunity for digital financial services providers, particularly fintechs leveraging technology to close the gender gap in financial services.
  • "Participating in the Women's World Banking Fintech Innovation Challenge drove us to learn moredeeply how we can better serve our women customers," said Rachel Freeman, Chief Growth Officer at Tyme, a 2020 Fintech Innovation Challenge Winner.
  • The Grand Prize winner of the Fintech Innovation Challenge will be announced in Dubai, on February 16, 2023 following the pitch competition.

Women's World Banking Announces 2023 Fintech Innovation Challenge to Elevate Fintechs with New Solutions to Close the Gender Gap in Financial Services

Retrieved on: 
Wednesday, August 3, 2022
Zero, Department of Foreign Affairs and Trade, Digital, Department, Marketing, Ernst & Young, Singapore FinTech Festival, DFAT, Swedish International Development Cooperation Agency, Female, Global Network for Rights and Development, Competition, Santa Clara University, Seumas McNally Grand Prize, Man, Women's World Banking, Policy, Economy, Foreign Affairs, Technology, SIDA, NEW, CEO, Challenge, Leadership, Prize, Global Television Network, Social entrepreneurship, UX, Empowerment, Bill, Growth, Birth control, Bank, TYME, Woman

NEW YORK, Aug. 3, 2022 /PRNewswire/ -- Women's World Banking announced today the 2023 Fintech Innovation Challenge, a global competition to highlight and advance solutions to close the gender gap through digital financial services. Now in its fourth year and the only women-centered fintechs competition, the Challenge will provide a platform for later stage fintechs working to address the persistent challenges in serving the low-income women's market.

Key Points: 
  • Digital financial services can serve as an on-ramp for low-income women to adopt and use a large suite of formal financial products and services, expanding women's choices and their financial and economic resilience and empowerment.
  • Low-income women represent a large, untapped market opportunity for digital financial services providers, particularly fintechs leveraging technology to close the gender gap in financial services.
  • "Participating in the Women's World Banking Fintech Innovation Challenge drove us to learn moredeeply how we can better serve our women customers," said Rachel Freeman, Chief Growth Officer at Tyme, a 2020 Fintech Innovation Challenge Winner.
  • The Grand Prize winner of the Fintech Innovation Challenge will be announced in Dubai, on February 16, 2023 following the pitch competition.